Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 372 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control - Inhibition Clear all
Withdrawn No phase listed Observational Accepts healthy volunteers

Immunomodulatory Effects of PCSK9 Inhibition

NCT05720156
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases, Atherosclerosis, Arterial Inflammation, Vascular Diseases, Vascular Disease, Peripheral, Vascular Calcification, High Cholesterol/Hyperlipidemia, Heart Diseases, Heart Attack, Stroke, Cerebrovascular Accident, Carotid Artery Diseases, Carotid Atherosclerosis, Transient Ischemic Attack
Interventions
99mTc-tilmanocept SPECT/CT scanning
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Not applicable Interventional Results available

Evaluating a Type 2 Diabetes Prevention Program

NCT05822648
View directory record Official record
Conditions
Type 2 Diabetes, PreDiabetes
Interventions
Project Health, Educational Video Control
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Results available

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))

NCT02729025
View directory record Official record
Conditions
Subjects With Hyperlipidemia, Dyslipidemia
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years to 80 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Miami, Florida • Las Vegas, Nevada • Mooresville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 21, 2026, 1:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Extending Dental Care to Nursing Home Residents to Reduce Mouth Infections and Incidence of Pneumonia and Improve Diabetic Glucose Control

NCT06890676
View directory record Official record
Conditions
Periodontitis, Gingivitis, Periodontal Disease, Periodontal Infections, Oral Infections, Periapical Infections, Pneumonia, Diabetes
Interventions
Comprehensive Oral Evaluation, Intraoral Complete Radiographic Series, • Teledentistry-synchronous and asynchronous, Periodontal Therapy, Periodontal Maintenance Procedure, Application of Caries Arresting Medicament, Oral Hygiene Assistance, Referral for Treatment of Acute Oral Infection
Other · Procedure
Lead sponsor
Missouri Department of Health and Senior Services
Other
Eligibility
60 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jefferson City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 21, 2026, 1:40 PM EDT
Active, not recruiting Not applicable Interventional

Improving PCP Advance Care Planning for People With ADRD

NCT06565169
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Alzheimer's Disease (Incl Subtypes), Aging
Interventions
Primary Care Team Advance Care Planning With People with Alzheimer's Disease or a Related Dementia Training, Care as Usual
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 99 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 2 Interventional

A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

NCT00271765
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
INO-1001
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
10
States / cities
Fort Lauderdale, Florida • Valparaiso, Indiana • Saint Paul, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2006 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Not applicable Interventional

Randomized Double-Blind Controlled Clinical Trial

NCT04320628
View directory record Official record
Conditions
Chronic Wounds, Acute Wounds
Interventions
AnaSept®, NSS
Device · Other
Lead sponsor
SerenaGroup, Inc.
Network
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Cerebrovascular Control

NCT02936687
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo
Drug · Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

NCT01258907
View directory record Official record
Conditions
Atherosclerosis
Interventions
MLDL1278A, placebo, statin, stable dose
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
22
States / cities
Torrance, California • Colorado Springs, Colorado • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 21, 2026, 1:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Acute and Chronic Repercussion of Spinal Cord Stimulation After Spinal Cord Injury

NCT07210411
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Tests of sympathetic inhibition, Tests of above level sympathetic activation, Testing of below level sympathetic activation, Epidural stimulation, Transcutaneous stimulation
Diagnostic Test · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 21, 2026, 1:40 PM EDT
Terminated Phase 4 Interventional

Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS

NCT00486343
View directory record Official record
Conditions
Asthma
Interventions
Zileuton CR, Placebo
Drug
Lead sponsor
Critical Therapeutics
Industry
Eligibility
12 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia

NCT03118466
View directory record Official record
Conditions
AML
Interventions
Etoposide, Cytarabine, Lenalidomide, Mitoxantrone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 21, 2026, 1:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural and Hormonal Influences on Sex Differences in Risk for AUD

NCT04929288
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Alcohol
Drug
Lead sponsor
Jessica Weafer
Other
Eligibility
21 Years to 26 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

NCT05156320
View directory record Official record
Conditions
Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin
Interventions
Apitegromab, Placebo
Drug
Lead sponsor
Scholar Rock, Inc.
Industry
Eligibility
2 Years to 21 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Not applicable Interventional Results available

Developing Effective Response Inhibition Training for Symptom Relief in OCD and Trichotillomania

NCT02059980
View directory record Official record
Conditions
Obsessive Compulsive Disorder, Trichotillomania
Interventions
Response inhibition training, Placebo Control Training
Behavioral
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
18 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 21, 2026, 1:40 PM EDT
Withdrawn Phase 1 Interventional

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

NCT05457959
View directory record Official record
Conditions
Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions
Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis, Nivolumab, Placebo Administration, Poly ICLC, Resection
Biological · Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
13 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 3 Interventional

STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)

NCT00124332
View directory record Official record
Conditions
Coronary Atherosclerosis
Interventions
Rimonabant (SR141716), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2009 · Synced Oct 21, 2026, 1:40 PM EDT
Not yet recruiting Phase 4 Interventional

Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)

NCT07424378
View directory record Official record
Conditions
Frostbite
Interventions
Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum, Standard of Care + Placebo (Normal Saline)infusion for 8 hours per day up to 5 days maximum
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 21, 2026, 1:40 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

NCT07169318
View directory record Official record
Conditions
Influenza
Interventions
Placebo for VNT-101, VNT-101
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 21, 2026, 1:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study of Dual-task Exercise Training to Prevent Falls Among Older Adults With Mild Cognitive Impairment

NCT05725668
View directory record Official record
Conditions
Mild Cognitive Impairment, Accidental Falls, Aging
Interventions
dual-task tai ji quan, standard tai ji quan, stretching
Behavioral
Lead sponsor
Oregon Research Institute
Other
Eligibility
65 Years to 95 Years
Enrollment
336 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Springfield, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

CYP2B6 Genetics and Drug Interactions in Healthy Volunteers

NCT02401256
View directory record Official record
Conditions
Healthy
Interventions
Efavirenz, Bupropion, Rosuvastatin, Montelukast
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Results available

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

NCT00390455
View directory record Official record
Conditions
Estrogen Receptor Positive, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Fulvestrant, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Placebo Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
368
States / cities
Little Rock, Arkansas • Arroyo Grande, California • Burbank, California + 259 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 21, 2026, 1:40 PM EDT
Recruiting Phase 2 Interventional

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

NCT06824064
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Advanced Colorectal Cancer
Interventions
RBS2418, Placebo
Drug
Lead sponsor
Riboscience, LLC.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Newark, Delaware • Kingwood, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 21, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Effect of Motor-Cognitive Training

NCT06017154
View directory record Official record
Conditions
Injury;Sports
Interventions
Motor-Cognitive Training Program
Other
Lead sponsor
Ke'La H Porter
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 21, 2026, 1:40 PM EDT